Epsilon Alpha
Bluelighter
I'm not so sure -- I think psychiatrists would be happy to prescribe a drug that is not schedule II if it worked as well. Modafinil unfortunately doesn't really fit the bill. It certainly treats ADHD symptoms, but in terms of effect size, it isn't really much better than atomoxetine. It doesn't really compare to the effect sizes produced by the psychostimulants. http://www.medscape.com/viewarticle/461543
As far as regulatory matters are concerned, I think if no children had developed stevens-johnsons syndrome during the 2006 clinical trial, it probably would have been approved for ADHD.
Those trials seemed really strange to me, I mean roughly 30% of the children reported rashes, and there were a couple possible cases of SJS that were not followed up for with biopsies. Also, with ~30000 off-label prescriptions in children as of 2007 and no reported cases of SJS and rashes being a rare side effect in the other populations... I'm not usually a conspiracy guy but I think there were some strings pulled to make atomoxetine the only "non-stimulant" ADHD drug on the market. Of the cases in younger individuals one had possible viral cause, one had other SJS causing medications and did not have a biopsy to confirm SJS (lamotrigine), and the last was on Zyprexa, Abilify, and Luvox (all known to have slight risks for SJS). Also, note how much is "unspecified" in the 15/M case.
http://www.fda.gov/Drugs/DrugSafety...afinilmarketedasProvigil:SeriousSkinReactions